Single-dose Intravenous Gammaglobulin Can Stabilize Neutrophil Mac-1 Activation in Sickle Cell Pain Crisis

Overview

Journal Am J Hematol

Specialty Hematology

Date 2015 Jan 24

PMID 25616042

Citations 22

Authors

Deepa Manwani

Grace Chen

Veronica Carullo

Stelian Serban

Olugbenga Olowokure

Jungeun Jang

Matthew Huggins

Hillel W Cohen

Henny Billett

George F Atweh

Paul S Frenette

Patricia A Shi

Affiliations

Soon will be listed here.

Abstract

Intravenous immunoglobulin (IVIG) decreases neutrophil adhesion to endothelium and red blood cell-neutrophil interactions in sickle cell mice undergoing vaso-occlusion. In this Phase I clinical trial of sickle cell anemia (SCA) patients admitted with pain crisis, we evaluated the status of adhesion molecules on neutrophils in control and IVIG-treated subjects pre- and post-infusion up to 800 mg/kg, the same dose used in murine studies. Mac-1 function significantly decreased from baseline in the low-dose IVIG (200-400 mg/kg) cohorts. IVIG-related adverse events may have occurred in the high-dose (600-800 mg/kg) cohorts. There were no significant increases in neutrophil and leukocyte counts, suggesting that IVIG may more selectively inhibit Mac-1 function as opposed to neutrophil adhesion. This study provides the first in-human validation of pre-clinical murine studies that IVIG can decrease Mac-1 function.

Citing Articles

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.

Barak M, Hu C, Matthews A, Fortenberry Y Cells. 2024; 13(10.

PMID: 38786070 PMC: 11120250. DOI: 10.3390/cells13100848.

Sickle cell vaso-occlusion: The dialectic between red cells and white cells.

Conran N, Embury S Exp Biol Med (Maywood). 2021; 246(12):1458-1472.

PMID: 33794696 PMC: 8243211. DOI: 10.1177/15353702211005392.

Sickle cell disease: progress towards combination drug therapy.

Pace B, Starlard-Davenport A, Kutlar A Br J Haematol. 2021; 194(2):240-251.

PMID: 33471938 PMC: 8282668. DOI: 10.1111/bjh.17312.

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.

Osunkwo I, Manwani D, Kanter J Ther Adv Hematol. 2020; 11:2040620720955000.

PMID: 33062233 PMC: 7534097. DOI: 10.1177/2040620720955000.

Drug Therapies for the Management of Sickle Cell Disease.

Rai P, Ataga K F1000Res. 2020; 9.

PMID: 32765834 PMC: 7388199. DOI: 10.12688/f1000research.22433.1.

References

Benkerrou M, Delarche C, Brahimi L, Fay M, Vilmer E, Elion J . Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood. 2002; 99(7):2297-303. DOI: 10.1182/blood.v99.7.2297. View

Turhan A, Jenab P, Bruhns P, Ravetch J, Coller B, Frenette P . Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood. 2003; 103(6):2397-400. DOI: 10.1182/blood-2003-07-2209. View

Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier J . Effects of intravenous immunoglobulins (IVIG) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol. 1994; 71(3):309-14. DOI: 10.1006/clin.1994.1091. View

Katayama Y, Hidalgo A, Chang J, Peired A, Frenette P . CD44 is a physiological E-selectin ligand on neutrophils. J Exp Med. 2005; 201(8):1183-9. PMC: 2213157. DOI: 10.1084/jem.20042014. View

Gill V, Doig C, Knight D, Love E, Kubes P . Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation. 2005; 112(13):2031-9. DOI: 10.1161/CIRCULATIONAHA.105.546150. View

Finnegan E, Turhan A, Golan D, Barabino G . Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion. Am J Hematol. 2006; 82(4):266-75. DOI: 10.1002/ajh.20819. View

Wun T, Styles L, DeCastro L, Telen M, Kuypers F, Cheung A . Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS One. 2014; 9(7):e101301. PMC: 4079300. DOI: 10.1371/journal.pone.0101301. View

Chang J, Shi P, Chiang E, Frenette P . Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood. 2007; 111(2):915-23. PMC: 2200843. DOI: 10.1182/blood-2007-04-084061. View

Hidalgo A, Peired A, Wild M, Vestweber D, Frenette P . Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity. 2007; 26(4):477-489. PMC: 4080624. DOI: 10.1016/j.immuni.2007.03.011. View

10.

Brousseau D, Owens P, Mosso A, Panepinto J, Steiner C . Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010; 303(13):1288-94. DOI: 10.1001/jama.2010.378. View

11.

Chang J, Patton J, Sarkar A, Ernst B, Magnani J, Frenette P . GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 2010; 116(10):1779-86. PMC: 2947397. DOI: 10.1182/blood-2009-12-260513. View

12.

Lin R, Rodriguez-Baez G, Bhargave G, Lin H . Intravenous gammaglobulin-associated renal impairment reported to the FDA: 2004 - 2009. Clin Nephrol. 2011; 76(5):365-72. DOI: 10.5414/cn106824. View

13.

Casulli S, Topcu S, Fattoum L, von Gunten S, Simon H, Teillaud J . A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One. 2011; 6(10):e26469. PMC: 3204983. DOI: 10.1371/journal.pone.0026469. View

14.

Sobota A, Graham D, Neufeld E, Heeney M . Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation. Pediatr Blood Cancer. 2011; 58(1):61-5. PMC: 4581528. DOI: 10.1002/pbc.23221. View

15.

Jang J, Hidalgo A, Frenette P . Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1. Circ Res. 2012; 110(8):1057-66. PMC: 3351009. DOI: 10.1161/CIRCRESAHA.112.266411. View

16.

Almeida C, Scheiermann C, Jang J, Prophete C, Costa F, Conran N . Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood. 2012; 120(14):2879-88. PMC: 3466969. DOI: 10.1182/blood-2012-02-409524. View

17.

Kolaczkowska E, Kubes P . Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013; 13(3):159-75. DOI: 10.1038/nri3399. View

18.

Funk M, Gross N, Gross S, Hunfeld A, Lohmann A, Guenay S . Thromboembolic events associated with immunoglobulin treatment. Vox Sang. 2013; 105(1):54-64. DOI: 10.1111/vox.12025. View

19.

Chopra V, Anand S, Hickner A, Buist M, Rogers M, Saint S . Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet. 2013; 382(9889):311-25. DOI: 10.1016/S0140-6736(13)60592-9. View

20.

Vichinsky E, Neumayr L, Earles A, Williams R, Lennette E, Dean D . Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000; 342(25):1855-65. DOI: 10.1056/NEJM200006223422502. View